Verve Therapeutics, INC Form 4 insider transactions

GV entities, including Alphabet Inc., reported the disposition of all their common stock in Verve Therapeutics, Inc. following the completion of Eli Lilly and Company's tender offer and subsequent merger.

Verve Therapeutics director Michael F. MacLean's stock options were cancelled and converted to cash and contingent value rights as a result of the merger with Eli Lilly and Company.

Verve Therapeutics, Inc. has completed its merger with Eli Lilly and Company, becoming a wholly-owned subsidiary, with shareholders receiving cash and contingent value rights.

Verve Therapeutics' Chief Financial Officer, Allison Dorval, reported the conversion of her equity holdings into cash and contingent value rights following the company's acquisition by Eli Lilly and Company.

Verve Therapeutics' Chief Administrative Officer, Joan Nickerson, disposed of all common stock, stock options, and restricted stock units following the company's acquisition by Eli Lilly and Company.

Verve Therapeutics, Inc. CEO Sekar Kathiresan has disposed of all his direct and indirect equity and derivative holdings in the company following the completion of its merger with Eli Lilly and Company's subsidiary.

Verve Therapeutics' Chief Scientific Officer, Troy Lister, reported the complete disposition of his beneficial ownership in company stock and equity awards as a result of the company's acquisition by Eli Lilly and Company, effective July 25, 2025.

Verve Therapeutics, Inc. has finalized its merger with Eli Lilly and Company, with shareholders receiving $10.50 per share in cash plus a contingent value right for potential additional payments.

Lonnel Coats' stock options in Verve Therapeutics were cancelled and converted to cash and non-tradeable contingent value rights as part of the company's merger with Eli Lilly and Company.

Verve Therapeutics director Jodie Pope Morrison received cash and contingent value rights from the cancellation of stock options following the company's merger with Eli Lilly and Company.

Andrew D. Ashe, President, COO, and General Counsel of Verve Therapeutics, Inc., converted all his common stock, stock options, and restricted stock units into cash and contingent value rights as a result of the company's merger with Eli Lilly and Company.

Verve Therapeutics, Inc. has completed its merger with Eli Lilly and Company, resulting in the conversion of all outstanding common stock, stock options, and restricted stock units into cash and contingent value rights.

A Verve Therapeutics director's stock options were cancelled and converted to cash and contingent value rights following the company's merger agreement with Eli Lilly and Company.

A Verve Therapeutics director's stock options were cancelled and converted to cash and contingent value rights as part of the company's merger with Eli Lilly and Company.

Verve Therapeutics director Alexander Cumbo's stock options were cancelled and converted to cash and contingent value rights following the merger with Eli Lilly and Company.

Verve Therapeutics, Inc. Director Alexander Cumbo was granted 42,200 stock options with an exercise price of $5.73 as part of the company's 2021 Stock Incentive Plan.

Verve Therapeutics, Inc. director Lonnel Coats was granted 42,200 stock options at an exercise price of $5.73 per share as part of the company's director compensation program.

Verve Therapeutics, Inc. director Jodie Pope Morrison was granted 42,200 stock options with an exercise price of $5.73 as part of the company's director compensation program.

Verve Therapeutics, Inc. director Sheila Mikhail was granted 42,200 stock options with an exercise price of $5.73 as part of the company's 2021 Stock Incentive Plan and director compensation program.

Verve Therapeutics, Inc. director Burt A. Adelman was granted 42,200 stock options as part of the company's 2021 Stock Incentive Plan and director compensation program.

Verve Therapeutics, Inc. Director Michael F. MacLean was granted 42,200 stock options with an exercise price of $5.73, vesting over one year or upon the next annual meeting, as part of the company's 2021 Stock Incentive Plan.

Verve Therapeutics, Inc. Director Ourania Tatsis was granted 42,200 stock options with an exercise price of $5.73, vesting over one year or prior to the next annual meeting, as part of the company's director compensation program.

Krishna Yeshwant, a Director and 10% Owner of Verve Therapeutics, Inc., was granted 42,200 stock options with an exercise price of $5.73 as part of the company's director compensation program.

Troy Lister, Chief Scientific Officer of Verve Therapeutics, reports the vesting and sale of common stock to cover tax obligations.

CEO Sekar Kathiresan reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Joan Nickerson, Chief Administrative Officer of Verve Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Andrew Ashe, President, COO, and General Counsel of Verve Therapeutics, reports the settlement of restricted stock units and a sale of shares to cover withholding tax liability.

Jason Politi, Chief Technical Operations Officer at Verve Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Chief Financial Officer of Verve Therapeutics, Allison Dorval, reports the settlement of restricted stock units and a sale of shares to cover tax obligations.

Verve Therapeutics' Chief Financial Officer, Allison Dorval, was granted stock options and restricted stock units on January 8, 2025, according to a recent SEC filing.